



Sanofi Organizes Workshop for DRAP on Vaccine Manufacturing

Islamabad, Pakistan- July 26th, 2017: Sanofi Pasteur, the vaccines business of the multinational pharmaceutical company Sanofi, in collaboration with Drug Regulatory Authority of Pakistan (DRAP) conducted a workshop on “The Science of Vaccine Manufacturing”.

Held at the DRAP office, the objective of the workshop was to highlight and educate the health authority on the complexities involved in vaccine manufacturing and the challenges faced by manufacturers in ensuring the steady supply of vaccines. The workshop was conducted by Ms. Brigitte Barbeau (Head of Sanofi Pasteur, Quality International Sites) and Mr. Pierre Lauer (Senior Director, International Quality Operations), both being experts on the subject matter and stationed at the Sanofi Pasteur manufacturing site in Lyon, France.

The workshop was attended by Dr. Muhammad Aslam (CEO, DRAP), Mr. Ghulam Rasool Dutani (Chairman Registration Board/Director PEC & CD, DRAP), Mr. Abdul Samad (Director, National Control Laboratory for Biologicals (NCLB), DRAP), Dr. Noor-us-Saba (Director Biologicals, DRAP), Dr. Asim Jamal (Country Chair & GM Sanofi Pakistan), & Dr. Nadim ur Rehman (Head of Medical Affairs, Sanofi Pakistan), amongst various other stakeholders.

The Government of Pakistan is enthusiastic for the indigenous production of vaccines and self-sufficiency in this regard for its national strategic goals and access to medicine/vaccine for needy patients. Dr. Aslam (CEO, DRAP) was appreciative of the session and noted, *“Vaccine manufacture remains one of the most complex procedures in the pharmaceutical industry but we have to face this challenge. We are thankful to Sanofi for conducting this insightful workshop for our regulatory staff for enhancing their skills and to update their knowledge base in this highly challenging and sensitive field. It is essential that the industry and DRAP continue to cooperate to ensure access to vaccines for the Pakistan market for universal coverage of its population, ultimately resulting in lower healthcare costs.”*

The international speakers Ms. Brigitte and Mr. Pierre frequently conduct such workshops with regulators around the world to develop better understanding on the complexities of vaccine manufacture.

Speaking on the occasion, Dr. Asim Jamal (Country Chair & GM, Sanofi Pakistan) said; *“Vaccines are considered to be one of the greatest medical achievements of modern civilization. According to WHO, vaccines avert an estimated 2 to 3 million deaths every year, globally.”* Citing the credo of Sanofi Pasteur and emphasizing its global footprint, Dr. Asim Jamal further said; *“At Sanofi, we believe in a world in which no one suffers or dies from a vaccine preventable disease. Sanofi is the world’s largest producer of seasonal influenza vaccines, with 200 million doses produced in 2016. With strict budgets and cost-*

containment issues for the Government, vaccines remain to be ideal solution for not only saving costs but also lives. With a strong pipeline of new vaccines we are positive that with the cooperation of DRAP we will launch the latest innovations such as the Dengue vaccine very soon in Pakistan. Sanofi Pasteur has already been granted marketing authorization for the first-ever dengue vaccine in 16 countries.”

Dr. Asim Jamal held out the assurance that Sanofi with its diverse vaccine portfolio aimed to work closely with the health authority in reducing the disease burden in Pakistan and contribute towards a progressive, healthier Pakistan.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: [SAN](#)) and in New York (NYSE: [SNY](#)).

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Contacts: Media Relations

Laila Khan

Tel. : +92 21 35060221-35 Ext. 2468

Laila.khan@sanofi.com